Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Greater baseline disease pruritus and quality of life impairment are associated with higher rates of super response to dupilumab in patients with AD.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

Patients from this diverse cohort experienced improvements in atopic dermatitis (AD) clinical scores after a year or more of treatment with dupilumab. Dupilumab was shown to be well-tolerated and ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed the safety and efficacy of the drug, which ...

NASHVILLE, Tennessee — For children with uncontrolled asthma on standard therapies and meeting criteria of a type 2 (T2) inflammatory phenotype, a prospective 1-year extension from a phase 3 trial ...